CN102247336B - Bufothionine dry powder inhaler, and its preparation method and application - Google Patents
Bufothionine dry powder inhaler, and its preparation method and application Download PDFInfo
- Publication number
- CN102247336B CN102247336B CN 201110147782 CN201110147782A CN102247336B CN 102247336 B CN102247336 B CN 102247336B CN 201110147782 CN201110147782 CN 201110147782 CN 201110147782 A CN201110147782 A CN 201110147782A CN 102247336 B CN102247336 B CN 102247336B
- Authority
- CN
- China
- Prior art keywords
- bufothionine
- lactose
- powder
- preparation
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XFIMEMVNMWDPRW-UHFFFAOYSA-O C1=C(OS(O)=O)C([N+](C)(C)CC2)=C3C2=CNC3=C1 Chemical compound C1=C(OS(O)=O)C([N+](C)(C)CC2)=C3C2=CNC3=C1 XFIMEMVNMWDPRW-UHFFFAOYSA-O 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 229940112141 dry powder inhaler Drugs 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims description 44
- OBRNDARFFFHCGE-QDSVTUBZSA-N arformoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-QDSVTUBZSA-N 0.000 claims description 40
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 38
- 239000008101 lactose Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 36
- 239000002775 capsule Substances 0.000 claims description 21
- 229960000193 formoterol fumarate Drugs 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 15
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000037841 lung tumor Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- -1 bufothionine Foradil Aerolizer formoterol fumarates Chemical class 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 17
- 210000004072 lung Anatomy 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 abstract description 6
- 238000010579 first pass effect Methods 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 230000002685 pulmonary effect Effects 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000008021 deposition Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241001415440 Bufo gargarizans Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- VOZHMAYHYHEWBW-NVOOAVKYSA-N Bufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)C=CC(=O)OC=1 VOZHMAYHYHEWBW-NVOOAVKYSA-N 0.000 description 2
- VOZHMAYHYHEWBW-UHFFFAOYSA-N Bufotalin Natural products CC(=O)OC1CC2(O)C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 VOZHMAYHYHEWBW-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007888 Sinus Tachycardia Diseases 0.000 description 2
- 206010040741 Sinus bradycardia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000007681 cardiovascular toxicity Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RYDFXSRVZBYYJV-TYYBGVCCSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O RYDFXSRVZBYYJV-TYYBGVCCSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000019610 cohesiveness Nutrition 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a dry powder inhaler, more specifically to a dry powder inhaler prepared by bufothionine, and relates to a preparation method for the drypowder inhaler and application of the dry powder inhaler in preparing medicines for treating tumors of lung. The bufothionine dry powder inhaler is characterized by comprising bufothionine and medically acceptable accessories, wherein the mass ratio of bufothionine to the accessories is in a range of 1:0.01 to 1:100. The application of bufothionine dry powder inhaler is mainly directed at tumors of lung, can directly act on an affected part and is free of first pass effect of liver, thereby reducing adverse reactions and having a great prospect in developing new medicines.
Description
Technical field:
The present invention relates to Foradil Aerolizer formoterol fumarate, specifically the preparation method of the Foradil Aerolizer formoterol fumarate made of bufothionine, described Foradil Aerolizer formoterol fumarate and the application in preparation treatment lung tumors medicine.
Background technology:
Cutis Bufonis is the dry skin of Bufonidae animal Bufo siccus Bufobufo gargarizans Cantor, effect with heat-clearing and toxic substances removing, diuretic relieving distension, the Cutis Bufonis water soluble part mainly contains bufothionine, N-phenyl-ethylnaphthalene amine, amino acids, and wherein bufothionine is one of its main component.Bufothionine is colourless acicular crystal, and its molecular formula is C
12H
14N
2O
4S is water miscible indole alkaloids in the Cutis Bufonis, and antitumor activity in vitro shows that the bufothionine tumor control rate is 87.06%.Water soluble ingredient is the existing a plurality of listings of the medicine of main exploitation in the Cutis Bufonis, and cinobufacin injection, oral liquid, tablet have been applied to clinically at present, and hepatocarcinoma, pulmonary carcinoma, gastric cancer etc. are had preferably effect.HUACHANSU ZHUSHEYE, from the water soluble preparation of Skin of Bufo bufo gargarizans through being processed into, treatment primary hepatocarcinoma and medium and advanced lung cancer obtain respectively 44% and 56% comprehensive effective percentage, and tumor body minification is respectively 10% and 16%, and chemotherapy and radiation is had synergism.Although the clinical untoward reaction of HUACHANSU ZHUSHEYE is less, but still exist the intravenous drip meeting local vein reaction to occur, cause that the instillation vein shrinks spasm and causes pain, long-time stimulus causes the vein nonspecific inflammation; Dermoreaction, main manifestations are urticaria and the infringement of skin blister sample; Secondly, the cardiovascular system reactions such as premature beat, sinus bradycardia, sinus tachycardia, atrioventricular block appear in small part patient, and the reason of generation may be that the cardiac toxicity that bufotalin a small amount of in the cinobufacin produces causes; In addition, injection need to use in hospital, and patient compliance is poor.And the cinobufacin oral formulations need be through the first pass effect of liver, and onset is slow, and the preparation bioavailability is lower.Bufothionine is one of effective ingredient of cinobufacin injection and oral formulations, but the content in existing injection and oral formulations is lower, and above-mentioned preparation can not directly act on lesions position, bufothionine can not be performed to maximum to the inhibitory action of tumor.
Pulmonary is the open organ of body, has great surface area, and alveolar wall is comprised of cell monolayer, so that drug molecule very easily enters blood, so the lung inhalation has the plurality of advantages such as rapid-action, that untoward reaction is little.(the drypowder inhalers of Foradil Aerolizer formoterol fumarate in the lung inhalation, DPIs) do not use propellant and solvent, the air-flow that produces by patient's autonomous respiration makes the drug powder atomizing, and then make drug powder be delivered to pulmonary, have use convenient, absorb rapidly, without liver firstly cross, the characteristics of rapid release and targeting location, be a kind of novel drug-supplying system.
The sickness rate of pulmonary carcinoma rises rapidly in worldwide, dies from that pulmonary carcinoma ranks first in the male patient of carninomatosis.Current antitumor drug great majority all are drug administration by injection, and this whole body administering mode causes the curative effect of medicine to reduce so that the targeting of medicine reduces, and untoward reaction increases.
Adopt site-specific delivery of drugs antitumor drug to be transported to the tumor patient part of human body, medicine is improved in the concentration of patient part, can reduce the therapeutic effect of the dosage of medicine, the toxic and side effects that reduces medicine, raising medicine, have great clinical value.Employing can directly be transmitted medicine the focus of pulmonary carcinoma through the inhalant of lung administering mode, is conducive to improve medicine to the curative effect of pulmonary carcinoma and reduces the toxic and side effects of its normal tissue.Through patent and non-patent literature retrieval both at home and abroad, have no the report of relevant this project like product.
Summary of the invention:
Goal of the invention: an object of the present invention is to provide pulmonary's dry powder inhaler formulations of bufothionine and preparation method thereof.Another object of the present invention provides the application of Foradil Aerolizer formoterol fumarate of the present invention in preparation treatment lung tumors medicine.
For the foregoing invention purpose, the invention provides following technical scheme:
A kind of bufothionine Foradil Aerolizer formoterol fumarate is characterized in that it is comprised of bufothionine and medically acceptable adjuvant, and the mass ratio of bufothionine and described adjuvant is 1: 0.01-1: 100.
Described bufothionine Foradil Aerolizer formoterol fumarate is characterized in that it is to add the suction powder that adjuvant is made by bufothionine, and the particle diameter of powder is with D
50Meter is between the 0.1-1000 micron.
Described adjuvant is selected one or more mixture in sugar, alcohol, aminoacid, phospholipid, surfactant, cyclodextrin, biodegradable polymer substance, magnesium stearate, stearic acid, hard ester fumaric acid sodium, micropowder silica gel, the Pulvis Talci.
Described sugar can be selected one or more mixture in galactose, lactose, glucose, fructose, sucrose, trehalose, the Raffinose; Described alcohol can be selected one or more mixture in mannitol, xylitol, maltose alcohol, the sorbitol; Described aminoacid can be selected one or more in glycine, Aspartic Acid, alanine, tryptophan, isoleucine, threonine, glutamic acid, phenylalanine, leucine, cystine, lysine, proline, the arginine; Described phospholipid can be selected one or more in soybean phospholipid, lecithin, phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, the synthetic phospholipid; Described surfactant can be selected one or more mixture in pulmonary surfactant such as dipalmitoyl phosphatidyl choline, DLPC, the cholesterol; Described polymer substance, can select the macromolecule that meets safety requirements, preferred biodegradable polymer substance is one or more mixture in albumin, starch, polylactic acid, poly lactic-co-glycolic acid, Polyethylene Glycol, poloxamer, hyaluronic acid, hyaluronate sodium, the sodium alginate for example.
Preferred mode is that described adjuvant is the mixture of different-grain diameter lactose, preferred mode is that described adjuvant is for sucking the mixture with lactose granule and micronization lactose, wherein the lactose granule mean diameter is at the 30-250 micron, micronization lactose mean diameter is at the 1-10 micron, the mass ratio of lactose granule and micronization lactose is 1000: 1-1: 1, and most preferred mode is that the mass ratio of lactose granule and micronization lactose is 100: 1-5: 1.
Described bufothionine Foradil Aerolizer formoterol fumarate, its preparation process is as follows:
Bufothionine is made powder by pulverizing or spray drying, and powder and adjuvant mix homogeneously are made to suck and are used powder, are packaged in capsule or bubble-cap or the Diskus; Perhaps with bufothionine and adjuvant mix homogeneously, make suction by pulverizing or spray drying and use powder, be packaged in capsule or bubble-cap or the Diskus; Perhaps with partial supplementary material mix homogeneously in bufothionine and the prescription, make powder by pulverizing or spray drying, residue adjuvant mix homogeneously is made to suck and is used powder in powder and the prescription, is packaged in capsule or bubble-cap or the Diskus.
Preferred bufothionine Foradil Aerolizer formoterol fumarate, its preparation process is as follows:
Bufothionine by pulverizing or spray drying is made powder, is made suction with the mixture mix homogeneously of the lactose of different-grain diameter or lactose granule and micronization lactose and used powder, be packaged in capsule or bubble-cap or the Diskus.
The application of described bufothionine Foradil Aerolizer formoterol fumarate in preparation lung tumors medicine.
Beneficial effect:
1, pulmonary is the open organ of body, has great surface area, and alveolar wall is comprised of cell monolayer, so that drug molecule very easily enters blood, so the lung inhalation has the plurality of advantages such as rapid-action, that untoward reaction is little.(the drypowder inhalers of Foradil Aerolizer formoterol fumarate in the lung inhalation, DPIs) do not use propellant and solvent, the air-flow that produces by patient's autonomous respiration makes the drug powder atomizing, and then make drug powder be delivered to pulmonary, have use convenient, absorb rapidly, without liver firstly cross, the characteristics of rapid release and targeting location, be a kind of novel drug-supplying system.Multiplex in the infection for the treatment of respiratory tract and pulmonary about Foradil Aerolizer formoterol fumarate at present, but have no report for the Foradil Aerolizer formoterol fumarate of lung tumors treatment.Simultaneously, through patent and non-patent literature retrieval both at home and abroad, have no the report of relevant this project like product.Present Cutis Bufonis extract injection, oral liquid, tablet have been applied to clinical, and hepatocarcinoma, pulmonary carcinoma, gastric cancer etc. are had preferably effect.Especially HUACHANSU ZHUSHEYE, from the water soluble preparation of Skin of Bufo bufo gargarizans through being processed into, treatment primary hepatocarcinoma and medium and advanced lung cancer obtain respectively 44% and 56% comprehensive effective percentage, and tumor body minification is respectively 10% and 16%, and chemotherapy and radiation is had synergism.Although the clinical untoward reaction of HUACHANSU ZHUSHEYE is less, but still exist the intravenous drip meeting local vein reaction to occur, cause that the instillation vein shrinks spasm and causes pain, long-time stimulus causes the vein nonspecific inflammation; Dermoreaction, main manifestations are urticaria and the infringement of skin blister sample; Secondly, the cardiovascular system reactions such as premature beat, sinus bradycardia, sinus tachycardia, atrioventricular block appear in small part patient, and the possible cause of generation is that the cardiac toxicity that bufotalin a small amount of in the cinobufacin produces causes.In addition, injection need to use in hospital, and patient compliance is poor.And oral formulations need be through the first pass effect of liver, and onset is slow, and the preparation bioavailability is lower.Bufothionine is one of effective ingredient of cinobufacin injection and oral formulations, but the content in injection and oral formulations is lower, and above-mentioned preparation can not directly act on lesions position, bufothionine can not be performed to maximum to the inhibitory action of tumor.And the dry powder inhaler formulations of bufothionine can directly act on affected part for lung tumors, and does not have the first pass effect of liver, does not have above-mentioned untoward reaction, so its new drug development has very big prospect.
2, bufothionine needs to be mixed into Foradil Aerolizer formoterol fumarate with adjuvant, find in the practical operation, because bufothionine is water soluble ingredient, easily moisture absorption, when bufothionine is crushed to certain particle size because of electrostatic interaction between the powder, cohesivenesss etc. affect medicine and are easy to reunite, and because surface area increases, hygroscopicity strengthens, therefore need to carry out proportioning with adjuvant, overcome the problem of moisture absorption caking, the applicant knows that through great many of experiments bufothionine and ratio of adjuvant are controlled in the particular range, and particularly adjuvant selects the mixture of lactose granule and micronization lactose can make the good Foradil Aerolizer formoterol fumarate of intake performance.
The specific embodiment
Below in conjunction with example the present invention is described in further detail, but scope of the present invention is not subjected to any restriction of these examples.
Embodiment 1
The preparation of inhalant: adopt comminution by gas stream to D bufothionine
90=5 microns, mix at 1: 8 in mass ratio with the lactose of particle diameter at the 45-100 micron, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 2
The preparation of inhalant: adopt comminution by gas stream to D bufothionine
90=5 microns, mix in 10: 80: 1 ratio at the leucine of 30-55 micron with lactose, the particle diameter of particle diameter at the 45-110 micron, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 3
The preparation of inhalant: adopt comminution by gas stream to D bufothionine
90=7 microns, mix in 1: 8 ratio with the leucine of particle diameter 50-165 micron, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 4
The preparation of inhalant: with bufothionine powder, lactose, mannitol, glycine, DLPC, lecithin, magnesium stearate in 1: 5: 5: 3: 0.5: 0.5: 0.1 ratio was mixed, and comminution by gas stream is to powder D
50=8 microns, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 5
The preparation of inhalant: bufothionine, lactose, cholesterol are mixed in 1: 10: 1 ratio, and comminution by gas stream is to powder D
50=7 microns, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 6
The preparation of inhalant: in bufothionine, add respectively lactose, polyethylene glycol 6000, the albumin of 4 times, 2 times, 3 times of quality, spray drying, powder D
50=8 microns, drug powder is packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 7
The preparation of inhalant: bufothionine drug powder, the particle diameter of mean diameter at the 5-10 micron mixed in 10: 85: 5 ratio at mannitol, the micronization silica gel of 5-100 micron, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 8
The preparation of inhalant: bufothionine drug powder, mannitol, leucine are mixed in 10: 90: 3 ratio, and it is an amount of to add water after the mixing, and spray drying obtains D
50Be 4.5 microns powder, with mean diameter be the lactose granule mixing of 125-150 micron, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 9
The preparation of inhalant: bufothionine powder, mannitol, glycine are mixed in 10: 100: 3 ratio, and it is an amount of to add water after the mixing, and spray drying obtains D
50Be 6.8 microns powder, with mean diameter be the lactose granule mixing of 75-125 micron, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 10
1, the preparation of inhalant: with bufothionine powder (D
90=6.7 microns), German U.S. agent is happy
70 lactose, micronization lactose (D
90=5.1 microns) mix in 6: 90: 5 ratio, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
2, the inhalant pulmonary deposition ratio is investigated
Investigate according to People's Republic of China's version pharmacopeia in 2010 prescriptive procedure, the pulmonary deposition ratio of bufothionine reaches 31.4%, places after 18 months under the room temperature condition, and the pulmonary deposition ratio of bufothionine does not have significant change.
Embodiment 11
1, the preparation of inhalant: with bufothionine powder (D
90=6.2 microns), German U.S. agent is happy
70 lactose, micronization lactose (D
90=5.8 microns) mix in 3: 72: 1 ratio, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
2, the inhalant pulmonary deposition ratio is investigated
Investigate according to People's Republic of China's version pharmacopeia in 2010 prescriptive procedure, the pulmonary deposition ratio of bufothionine reaches 28.5%, places after 18 months under the room temperature condition, and the pulmonary deposition ratio of bufothionine does not have significant change.
Embodiment 12
1, the preparation of inhalant: with bufothionine powder (D
90=6.5 microns), German U.S. agent is happy
70 lactose, micronization lactose (D
90=5.4 microns) mix in 1: 65: 13 ratio, be packaged into behind the mix homogeneously in capsule or bubble-cap or the Diskus, obtain inhalant.
2, the inhalant pulmonary deposition ratio is investigated
Investigate according to People's Republic of China's version pharmacopeia in 2010 prescriptive procedure, the pulmonary deposition ratio of bufothionine reaches 29.4%, places after 18 months under the room temperature condition, and the pulmonary deposition ratio of bufothionine does not have significant change.
Embodiment 13
The preparation of inhalant: with bufothionine powder (D
50=5.5 microns), leucine (D
50=215 microns) mix the D of granule after mixing in 1: 8 ratio
50Be 225 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 14
The preparation of inhalant: bufothionine is mixed comminution by gas stream, powder D with leucine in 1: 1 ratio
90Below 5 microns, this powder is mixed again the D of granule after mixing with the mannitol of 8 times of amounts
50Be 279 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 15
The preparation of inhalant: bufothionine is mixed comminution by gas stream, powder D with poloxamer in 8: 1 ratio
90Below 8 microns, this powder is mixed again the D of granule after mixing with the lactose granule of 10 times of amounts, the magnesium stearate of 1 times of amount
50Be 301 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 16
The preparation of inhalant: with the bufothionine comminution by gas stream, powder D
90=6 microns, this powder is mixed again the D of granule after mixing with the lactose granule of 15 times of amounts
50Be 75 microns, be packaged in capsule or bubble-cap or the Diskus, obtain inhalant.
Embodiment 17
Obtain inhalant according to embodiment 1-16, carry out pharmacodynamic experiment.
Effect experiment:
The method of benzopyrene percutaneous puncture pulmonary injection is set up the induced lung animal model for tumour, gets 190 of modeling rats, is divided at random 19 groups, 10 every group.Every day 1 time, medication 7 days.The inhalant inhalation that administering mode: 1-16 group obtains for embodiment 1-16, dosage is 1mg bufothionine/kg; The 17th group of lumbar injection bufothionine, dosage is 1mg bufothionine/kg; The 18th group of gavage gives bufothionine, and dosage is 1mg bufothionine/kg; The 19th group is physiology saline control group, lumbar injection 10mL/kg.Next day is put to death rat in drug withdrawal, dissects lungs, observes the lung lesion situation.
Experimental result: it is 15% that the pulmonary of rat of each group of inhalant administration the incidence rate of lump or nodular lesion occurs minimum, is up to 35%; Bufothionine injection group is 55%, bufothionine gavage group is 65%, the normal saline group is 100%, and each group of inhalant administration has significant difference (P＜0.05) with bufothionine injection group, bufothionine gavage group, normal saline group in the pulmonary lesion incidence rate.
Embodiment 18
Obtain inhalant according to embodiment 1-16, carry out pharmacodynamic experiment.
1, the foundation of rabbit VX2 original position lung cancer model
1) the freezing cell suspension of the conventional recovery VX2 tumor of the making of lotus tumor kind rabbit makes 10
6The living cells suspension of/mL is got 1mL and is inoculated in 1 rabbit right rear leg outside intramuscular, can lay one's hand on and the lump of a diameter 30cm in inoculation position after 3 weeks, namely makes lotus tumor kind rabbit.
2) cut the intramuscular tumor in the lotus tumor kind rabbit leg outside under the preparation aseptic condition of piece of tissue suspension, get to be and oppress the eugonic tumor tissues of sample, be cut into the mud shape.30 mesh sieves were descended in the flushing of RPMI RPMI-1640, removed individual cells and too small piece of tissue, and part was descended 20 mesh sieves in the flushing of RPMI RPMI-1640 on the sieve, removed excessive piece of tissue.Get the lower part of screen and divide, after the centrifugation, taking precipitate 2mL adds the RPMI RPMI-1640 and is mixed with piece of tissue suspension 20mL.
3) all rabbit right thoracic wall depilations of inoculation in the lung, intramuscular injection speed is slept and is fixed after new mixture 0.8mL/kg anaesthetizes, routine disinfection, get aseptic three way cock, connecing respectively No. 12 injection needles, suctions has the 1mL syringe of rabbit self blood clot and the syringe that suction has VX2 tumor tissue suspension or cell suspension 1mL.Under X-ray examination, No. 12 syringe needles are thrust in the rabbit inferior lobe of right lung, behind the resorption depletion of blood, inject 0.4mL piece of tissue suspension or cell suspension, then inject 0.2mL rabbit self blood clot, extract syringe needle, inoculate complete.
4) the whole rabbit of the observation of growth of xenografted situation were from after the inoculation the 3rd day, and carry out layer wide, bed thickness be 5mm CT scan to chest every day, observed transfer case in tumor growth, the thoracic cavity.
5) rabbit VX2 original position lung cancer model is set up as a result rabbit all tumor growth in the lung, success ratio of inoculation 100%.
2, pharmacodynamic experiment
Get successfully 190 of modeling rabbit, be divided at random 19 groups, 10 every group.Every day 1 time, medication 12 days.The inhalant inhalation that administering mode: 1-16 group obtains for embodiment 1-16, dosage is 1mg bufothionine/kg; The 17th group of lumbar injection bufothionine, dosage is 1mg bufothionine/kg; The 18th group of gavage gives bufothionine, and dosage is 1mg bufothionine/kg; The 19th group is physiology saline control group, lumbar injection 10mL/kg.Next day is put to death rabbit in drug withdrawal, dissects the rabbit lungs, peels off tumor tissues, weighs, and calculates tumour inhibiting rate.
Experimental result: the tumour inhibiting rate minimum of each group of inhalant administration is 55.9%, is up to 65.9%; The tumour inhibiting rate of bufothionine injection group is 48.7%, the tumour inhibiting rate of bufothionine gavage group is 28.6%, without obvious inhibition, each group of inhalant administration has significant difference (P＜0.05) with the tumour inhibiting rate of bufothionine injection group, bufothionine gavage group, normal saline group to the normal saline group to tumor.
Claims (5)
1. a bufothionine Foradil Aerolizer formoterol fumarate is characterized in that it is by D
50Be that 6.7 microns bufothionine powder, German U.S. agent are happy
70 lactose, D
50The micronization lactose that is 5.1 microns forms, and three's ratio is 6: 90: 5.
2. a bufothionine Foradil Aerolizer formoterol fumarate is characterized in that it is by D
50Be that 6.2 microns bufothionine powder, German U.S. agent are happy
70 lactose, D
50The micronization lactose that is 5.8 microns forms, and three's ratio is 3: 72: 1.
3. a bufothionine Foradil Aerolizer formoterol fumarate is characterized in that it is by D
50Be that 6.5 microns bufothionine powder, German U.S. agent are happy
70 lactose, D
50The micronization lactose that is 5.4 microns forms, and three's ratio is 1: 65: 13.
4. method for preparing claim 1 or 2 or 3 described a kind of bufothionine Foradil Aerolizer formoterol fumarates, its preparation process is as follows: bufothionine is made powder by pulverizing or spray drying, make suction with the mixture mix homogeneously of lactose granule and micronization lactose and use powder, be packaged in capsule or bubble-cap or the Diskus.
5. according to claim 1 and 2 or the application of a kind of bufothionine Foradil Aerolizer formoterol fumarate of 3 in preparation treatment lung tumors medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110147782 CN102247336B (en) | 2011-06-02 | 2011-06-02 | Bufothionine dry powder inhaler, and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110147782 CN102247336B (en) | 2011-06-02 | 2011-06-02 | Bufothionine dry powder inhaler, and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102247336A CN102247336A (en) | 2011-11-23 |
| CN102247336B true CN102247336B (en) | 2013-03-13 |
Family
ID=44975147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110147782 Expired - Fee Related CN102247336B (en) | 2011-06-02 | 2011-06-02 | Bufothionine dry powder inhaler, and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102247336B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1068043A (en) * | 1991-06-22 | 1993-01-20 | 吴玉琢 | A kind of method and special implement thereof that extracts Venenum Bufonis |
| CN101176739A (en) * | 2006-11-08 | 2008-05-14 | 山东绿叶制药有限公司 | Toadpoison ligand extract as well as preparation method and application thereof |
| CN101822693A (en) * | 2010-04-29 | 2010-09-08 | 周莹 | Medicine treating tympanitis |
-
2011
- 2011-06-02 CN CN 201110147782 patent/CN102247336B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1068043A (en) * | 1991-06-22 | 1993-01-20 | 吴玉琢 | A kind of method and special implement thereof that extracts Venenum Bufonis |
| CN101176739A (en) * | 2006-11-08 | 2008-05-14 | 山东绿叶制药有限公司 | Toadpoison ligand extract as well as preparation method and application thereof |
| CN101822693A (en) * | 2010-04-29 | 2010-09-08 | 周莹 | Medicine treating tympanitis |
Non-Patent Citations (2)
| Title |
|---|
| 史宁等.干粉吸入剂的研究进展.《中国新药杂志》.2007,(第12期), * |
| 王振旺等.从上市产品分析干粉吸入剂的研究进展.《医药导报》.2007,(第03期), * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102247336A (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010111807A1 (en) | A polysaccharide liposome, the preparation method and use of it | |
| CN102058566A (en) | Dry powder inhaler with constituent rubescensin A as well as preparation method and application thereof | |
| CN102247335B (en) | Bufalin dry powder inhalant as well as preparation method and application thereof | |
| CN101322681B (en) | Method for preparing nano micelle formulation of anthracene nucleus antineoplastic antibiotic | |
| CN102302475B (en) | Resibufogenin dry powder inhalant and preparation method and application thereof | |
| CN102247336B (en) | Bufothionine dry powder inhaler, and its preparation method and application | |
| CN102302477B (en) | Cinobufagin dry power inhaler and preparation method and application thereof | |
| CN102961409B (en) | Toad skin extract dry powder inhaler | |
| CN102247337B (en) | Bufotalin dry powder inhalers and preparation method as well as application thereof | |
| CN103664936A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN102302476B (en) | Dehydrobufotenine dry power inhaler and preparation method and application thereof | |
| CN102210712B (en) | A kind of toad skin extract dry powder inhalation agent and its preparation method and application | |
| CN102961406B (en) | Toad skin extract dry powder inhaler, as well as preparation method and application thereof | |
| CN103083286B (en) | Toad venom lipophilic extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102210711B (en) | A dry powder inhaler of toad venom fat-soluble extract and its preparation method and application | |
| CN102961408B (en) | Toad skin extract dry powder inhaler | |
| CN103070885B (en) | Toad skin extract dry-powder inhalant and its preparation method and use | |
| CN103142652B (en) | Venenum bufonis fat-soluble extract dry powder inhaler, and preparation method and application thereof | |
| CN103070886B (en) | Toad skin extract dry-powder inhalant and its preparation method and use | |
| CN102973605B (en) | Toad skin extract dry powder inhalant and preparation method and applications thereof | |
| CN102973604B (en) | Toad skin extract dry powder inhalant and preparation method and applications thereof | |
| CN102988419A (en) | Toad skin extract powder inhalant, and preparation method and application thereof | |
| CN102309469A (en) | Baohuoside I dry powder inhalant as well as preparation method and application thereof | |
| CN102961407B (en) | Toad skin extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102091062A (en) | Method for treating lung cancer by sucking and administrating taxol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |